Comment to Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trials
- 222 Downloads
Abdel-Rahman  analyzed the overall survival-rate and disease-free survival of T1-2 N1 breast cancer patients after mastectomy, who were adjuvantly treated with various modern chemotherapeutic drugs (anthracyclines, taxanes) in 3 prospective phase III chemotherapy trials. His analysis suggested no potential benefits of an additional adjuvant postmastectomy radiotherapy (PMRT). The included trials were the BIG 02/98 , the BCIRG 001  and the BCIRG-005  trials. The author concludes that in T1-2 N1 breast cancer patients who have received modern chemotherapy drugs PMRT does not provide any benefit for overall and disease-free survival. Prospective studies are necessary.
PMRT has shown a survival benefit in many randomized trials and meta-analyses, in addition to a reduction in locoregional recurrence rate (LRR) in locally advanced breast cancer. The Early Breast Cancer Trialist’ Collaborative Group (EBCTCG) demonstrated that PMRT resulted in a reduction in LRR after...
Conflict of interest
C. Matuschek, D. Krug, R.J. Klement and R. Baumann declare that they have no competing interests.
- 4.Early Breast Cancer Trialists’ Collaborative Group, Mcgale P, Taylor C et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383:2127–2135CrossRefGoogle Scholar
- 5.Eiermann W, Pienkowski T, Crown J et al (2011) Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2‑normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29:3877–3884CrossRefPubMedGoogle Scholar
- 6.Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P et al (2012) Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 14:R70CrossRefPubMedPubMedCentralGoogle Scholar